This article is general legal information, not legal advice; consult a licensed attorney about your specific claim. Unless a figure is labeled with another year inline, all settlement and fee figures reflect data verified for 2023–2026.
TL;DR — Quick Verdict
- A mass tort keeps your claim individual, so a severe injury can recover six figures; a class action splits one pot, and the average member often nets a few hundred dollars — one 2026 data-breach class paid roughly $489 per person.
- 3M’s Combat Arms earplug mass tort settled for $6.0 billion across roughly 260,000 claimants (3M, 2023); each veteran’s award was scaled to their hearing-loss severity — not divided equally.
- Contingency fees run 33% before a lawsuit is filed and 40% after (industry standard), plus an MDL common benefit assessment of roughly 3%–11% that comes out of the attorney’s share, not yours.
- Class action wins for small, identical financial losses; mass tort wins for serious physical injury where damages vary person to person.
- Recommendation: if your harm is a physical injury from a drug, device, or chemical, pursue a mass tort with your own attorney; if it’s a small uniform overcharge or data breach, the class action is the practical path.
Two lawsuits can target the same company for the same product and pay wildly different amounts to the people who were harmed. When Bayer resolved the bulk of its Roundup cancer claims in 2020, it committed up to $10.9 billion to roughly 125,000 filed and unfiled claims — an average near six figures each, because those were mass tort claims scaled to individual cancer diagnoses (Bayer, June 2020). Compare that to a securities class action, where the 2024 median settlement was $14 million spread across every shareholder who bought during the class period, often producing checks worth pennies on the dollar (Law360, 2024).
The label matters more than most claimants realize. “Mass tort” and “class action” are not synonyms, and choosing the wrong framework — or misunderstanding which one your case falls under — can cost you the difference between a life-changing recovery and a token payment. This article breaks down the structural differences, the real payout math, the fee deductions that shrink your net check, and which vehicle actually serves your situation.
The Core Structural Difference: One Claim vs Many Claims
A class action treats a large group as a single legal unit. One or a few named plaintiffs — the class representatives — litigate on behalf of everyone, and the outcome binds all members unless they formally opt out. Federal class actions must clear the litigation stages that govern timing and satisfy Rule 23 of the Federal Rules of Civil Procedure: numerosity (courts generally accept 40-plus members), commonality, typicality, and adequacy of representation (Cornell Legal Information Institute).
A mass tort works differently. Each injured person keeps a separate lawsuit with their own damages, even when hundreds of cases are consolidated before one judge for pretrial efficiency. That consolidation is called multidistrict litigation, or MDL, and it is coordinated — not merged — by the U.S. Judicial Panel on Multidistrict Litigation. Your case shares discovery and bellwether trials with the group, but your compensation reflects your specific injury, medical history, and losses.
The practical consequence is straightforward: in a class action, individual injury severity barely moves your share; in a mass tort, it drives it. Someone with catastrophic harm is generally better served keeping an individual claim rather than averaging into a class.
Payout Data: What Each Structure Actually Pays
Numbers make the gap concrete. The table below pairs real settlements with their per-claimant reality, drawn from company disclosures and litigation trackers.
Sources: 3M Company investor disclosures (verify at investors.3m.com); Bayer (verify at bayer.com); Law360 / Federal Judicial Center class-action analysis 2024 (verify at law360.com). Individual mass tort awards vary by severity and are not evenly divided.
Read the table by column, not by headline. The $10.3 billion PFAS class figure dwarfs many mass tort totals, yet nearly none of it reaches an individual person — it funds municipal water treatment. Meanwhile the smaller-looking 3M earplug settlement payouts for claimants produced substantial individual checks precisely because the money was allocated case by case.
How Compensation Gets Determined in Each Model
Picture two claimants, “Dana” and “Sam,” harmed by the same defective product. In a class action, Dana and Sam sit inside one certified class. The court approves a lump settlement, an administrator applies a formula, and both receive similar shares even if Dana’s losses were ten times Sam’s — unless the plan carves out tiers, which many do not.
Now run the same two people through a mass tort. Dana’s attorney documents a severe, permanent injury with extensive medical records; Sam’s file shows a milder, resolved condition. A settlement grid — the kind used in the Roundup lawsuit status and payout data — assigns points for diagnosis, exposure duration, age, and causation strength. Dana lands in a high tier worth six figures; Sam settles for a fraction. Same defendant, same product, radically different outcomes, because mass tort compensation is measured individually.
That grid logic explains why NEC baby formula claims and settlement projections and talcum powder settlements and deadlines publish injury-tier ranges rather than a single number. The framework rewards documented severity — a structure a class action’s shared-recovery model deliberately flattens.
Attorney Fees and Net Recovery: The Deductions That Shrink Your Check
Gross settlement is not take-home. In both structures, lawyers work on contingency, and the deductions differ in ways that matter.
Mass tort contingency fees follow a well-established pattern: roughly 33% of the recovery if your case resolves before a lawsuit is filed, and 40% once litigation begins, with the broader market ranging from 25% to 40% (Duke Law; industry fee surveys). On top of that, MDL cases carry a common benefit fund assessment — compensation for the leadership attorneys who ran depositions and bellwether trials for everyone — typically 3%–11% of gross recovery, commonly landing around 4%–8% (federal MDL court orders). Critically, that assessment comes out of the attorney’s fee, not your net check, unless a court order says otherwise.
Source: Duke University School of Law, MDL Common Benefit Funds; federal MDL common benefit orders (verify at uscourts.gov). Ranges reflect common structures; your signed fee agreement controls.
One detail decides your real net: whether the fee applies to gross or net proceeds. On a $100,000 recovery with $10,000 in costs, a 30% gross fee leaves you $60,000; a 30% net fee leaves you $63,000. Read the mass tort attorney fee structure and net recovery language before you sign.
Mass Tort vs Class Action: Which Is Better for a Serious Personal Injury?
Take the situation that sends most people searching: a real physical injury — cancer, organ damage, a device failure — tied to a specific product. Which structure serves you?
Class action strengths are efficiency and access. You typically do nothing but file a claim form, hire no attorney of your own, and share in a court-supervised fund. That is ideal when thousands of people suffered the same small, uniform loss — a $40 overcharge, an identical data breach — where individual lawsuits would cost more than they could ever recover.
Mass tort strengths are individualization and upside. Your damages are documented and valued on their own facts, so severe harm commands severe compensation. The trade-off: you retain your own lawyer, the process runs for years, and you shoulder more active involvement. For anyone weighing Camp Lejeune claim eligibility and case values or paraquat lawsuit eligibility and settlement outlook, that individualized valuation is the whole point.
Verdict
For a serious, well-documented physical injury, the mass tort wins decisively. Averaging a catastrophic injury into a shared class fund almost always underpays it, while the mass tort’s individual valuation lets a strong case reach six or seven figures. Reserve the class action for small, identical financial harms where the cost of an individual suit would exceed any realistic recovery — there, its efficiency is the advantage, not its per-person payout.
What Most People Get Wrong About the Difference
Confusion here is expensive. Five mistakes recur.
Mistake 1: Assuming “class action” and “mass tort” are the same thing. Consequence: people expect an equal split when their injury deserves individual valuation, or vice versa. Correct action: identify whether your harm is a uniform financial loss (class) or a variable physical injury (mass tort) before choosing counsel.
Mistake 2: Believing a bigger total settlement means a bigger personal check. Consequence: a claimant sees “$10.3 billion” and expects a windfall, not realizing the money went to water utilities. Correct action: ask what the per-claimant allocation is, not just the headline total.
Mistake 3: Not reading whether fees apply to gross or net. Consequence: thousands of dollars silently lost to the fee-calculation method. Correct action: confirm the basis in writing before signing.
Mistake 4: Missing the opt-out or filing deadline. Consequence: staying in a class action that undervalues your injury, or losing standing entirely. Correct action: track deadlines and understand how talc bankruptcy trust payments affect a claim when a defendant restructures.
Mistake 5: Responding to unsolicited “you qualify” calls or texts. Consequence: scam intake operations and inflated referral chains. Correct action: use the process for verifying mass tort claims and avoiding scam solicitations before sharing any personal or medical detail.
Who Should Pursue Each — and Is It Worth It?
Run your situation through simple conditional logic.
Pursue a class action if: your loss is small and identical to many others; it is primarily financial (an overcharge, a fee, a breach); and an individual lawsuit would cost more than you could recover. Here the class is worth it because it is the only economically rational path — no lawyer would take your $200 claim alone.
Pursue a mass tort if: you suffered a genuine physical injury; your damages differ meaningfully from other victims’; and you can document diagnosis, exposure, and causation. This describes emerging dockets like hair relaxer lawsuit eligibility and status, social media addiction lawsuit claims and status, and the long-running mesothelioma settlement amounts for asbestos victims. It is worth it when your individually valued claim would clearly exceed a flat class share — which, for serious injury, is nearly always.
The edge cases are drug and device claims where litigation status shifts fast, such as Zantac lawsuit status and settlement updates or PFAS water contamination lawsuit eligibility and settlements. There, worth-it depends on where the litigation sits today; a case with strong bellwether results and an active settlement grid is very different from one still fighting causation.
Frequently Asked Questions
Can the same product spawn both a class action and a mass tort?
Yes. A defective product can generate a class action for uniform economic losses (say, refunds) and a separate mass tort for personal injuries. Roundup illustrates the split: Bayer’s 2020 mass tort resolution addressed roughly 125,000 individual cancer claims, while a separate class agreement was structured to handle future claimants (Bayer, 2020). Which one you belong to depends on the nature of your harm.
Do I need my own lawyer for a class action?
Usually not. In a class action, the named plaintiffs’ attorneys — class counsel — represent every member, and the court approves their fee from the common fund. You typically just file a claim form. In a mass tort, you should retain your own attorney so your individual injury is fully documented, since contingency fees there commonly run 33% before filing and 40% after.
Why did some 3M earplug claimants get very different amounts?
Because the $6.0 billion 3M settlement was a mass tort, not an equal-split class action (3M, 2023). Awards across the roughly 260,000 claimants were scaled to hearing-loss severity, documentation, and whether the claim proceeded through the settlement grid. Two veterans with different injuries received different amounts — the defining feature of mass tort compensation.
What does the common benefit fund cost me?
In most MDLs, nothing extra directly. The common benefit assessment — typically 3%–11% of gross recovery — compensates leadership attorneys and comes out of your own lawyer’s contingency share, not your net check, unless a court order specifies otherwise (federal MDL orders). Some courts pass through a small cost component of one to two percentage points; your fee agreement should spell this out.
How We Researched This Article
We built this comparison from primary and authoritative secondary sources, prioritizing company disclosures and federal court materials over aggregators. Settlement totals and claim counts for the 3M Combat Arms earplug litigation come directly from 3M Company investor press releases and its FY2023 Form 10-K filed with the U.S. Securities and Exchange Commission. Roundup settlement figures — the up-to-$10.9 billion 2020 resolution and its approximately 125,000 filed and unfiled claims — come from Bayer’s own June 2020 announcement, cross-checked against litigation trackers for the 2026 proposed $7.25 billion class settlement.
The class certification framework (numerosity, commonality, typicality, adequacy) is drawn from the text of Federal Rule of Civil Procedure 23 and the Congressional Research Service’s summary. Contingency fee ranges and common benefit fund mechanics reflect Duke University School of Law materials on MDL common benefit funds and published federal MDL common benefit orders. Class action median settlement data for 2024 reflects Law360 and Federal Judicial Center analyses.
Key sources are linked here for verification: Cornell Legal Information Institute — Federal Rule 23, 3M FY2023 Form 10-K (SEC), and Bayer’s 2020 Monsanto litigation resolution announcement.
Limitations: individual payout figures are modeled ranges, not guarantees — mass tort awards depend on injury severity, documentation, and settlement-grid tiers that vary by litigation. Class action per-member amounts depend on claim rates and fund size. Where sources conflicted, we reported ranges. This research was last conducted August 2026. All figures were verified against named primary sources before publication.